Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35 GBX | -2.78% | -10.26% | +52.17% |
05-08 | EARNINGS: International Biotechnology bullish; Andrews Sykes profit up | AN |
03-20 | Cornerstone FS plans to change name to Finseta as part of growth plan | AN |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company has insufficient levels of profitability.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+52.17% | 25.87M | - | ||
+10.39% | 321B | B- | ||
+26.23% | 222B | B+ | ||
+3.24% | 148B | B | ||
+14.54% | 59.26B | D+ | ||
+15.37% | 31.8B | C+ | ||
+3.07% | 29.89B | B+ | ||
+89.66% | 22.41B | D+ | ||
+28.33% | 20.98B | B- | ||
+2.17% | 15.07B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- CSFS Stock
- Ratings Cornerstone FS plc